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OBJECTIVES The goal of this research was to clarify whether the benefit of reperfusion therapy for
myocardial infarction was sustained long-term and to assess the gain in life expectancy by
reperfusion therapy.
BACKGROUND Reperfusion therapy in acute myocardial infarction reduces infarct size and increases hospital
survival.
METHODS We analyzed the 20-year outcome of 533 patients (mean age 56 years; 82% men) who were
randomized to either reperfusion therapy or conventional therapy during the years 1981 to
1985.
RESULTS Mean follow-up was 21 years (range 19 to 23 years). At follow-up, 101 patients (36%) of the
269 patients allocated to reperfusion treatment and only 71 patients (26%) of the 264
conventionally treated patients were alive (p  0.02). The cumulative 10-, 15-, and 20-year
survival rates were 69%, 48%, and 37% after reperfusion therapy and 59%, 38%, and 27% in
the control group, respectively (p 0.005). Life expectancy of the reperfusion group was 15.2
years versus 12.4 years in the conventionally treated group (p  0.0001). Myocardial
re-infarction and subsequent coronary interventions were more frequent after reperfusion
therapy, particularly during the first year. In multivariable analysis, reperfusion therapy was an
important independent predictor of lower mortality at long-term follow-up (hazard ratio 0.7;
95% confidence interval 0.6 to 0.8). Other independent predictors of mortality were age,
impaired left ventricular function, multivessel disease, infarct size, and inability to perform an
exercise test at the time of discharge.
CONCLUSIONS This is the first study demonstrating sustained (20-year) improved survival after reperfusion
therapy. The gain in life expectancy was almost three years, representing about one-third of
the life-years lost by myocardial infarction. (J Am Coll Cardiol 2005;46:15–20) © 2005 by
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.047the American College of Cardiology Foundation
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educes infarct size, preserves left ventricular function, and,
ence, increases hospital survival by rapid restoration of
oronary flow distal to the culprit lesion (1–3). This survival
enefit is maintained during the first decade (4–7). How-
ver, in order to assess the gain in life expectancy by
eperfusion therapy, longer follow-up is necessary. There-
ore, we conducted a 20-year follow-up of patients partici-
ating in the study of reperfusion therapy by the Interuni-
ersity Cardiology Institute of the Netherlands (ICIN)
1981 to 1985) (1). The aim of this 20-year follow-up study
as to investigate whether the benefit of early reperfusion
herapy was sustained in the second decade and to assess the
ain in life expectancy by reperfusion therapy (4,8).
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etherlands; †University Hospital Maastricht, Maastricht, the Netherlands; ‡VU
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ity Medical Center Leiden, Leiden, the Netherlands. The Interuniversity Cardiology
nstitute of the Netherlands funded the original study.F
Manuscript received January 18, 2005; revised manuscript received March 3, 2005,
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tudy population. From 1981 to 1985, 533 patients in five
articipating hospitals were randomized to either immediate
eperfusion therapy (n  269) or conventional treatment
n  264). The study design and initial results have been
reviously reported (1). Acute coronary angiography was
erformed in 233 of 269 patients allocated to reperfusion
herapy. If the infarct-related coronary artery appeared to be
ccluded, streptokinase (250,000 U) was administered in-
racoronary. In the last 117 patients, intracoronary admin-
stration was preceded by intravenous streptokinase
500,000 U). In 46 patients with severe residual stenosis of
he infarct-related coronary artery, coronary angioplasty was
ttempted as part of the re-canalization procedure (1,9,10).
ollow-up. Follow-up vital status was obtained by review-
ng the hospital records and from general practitioners and
ivil registries. Data were collected on death, recurrent MI,
nd coronary revascularization procedures. The diagnosis of
ecurrent MI was based on the opinion of the treating
hysician and verified from hospital discharge letters, when
vailable. If necessary, patients were contacted by telephone.
ollow-up was complete in 99%. Survival status of four
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Sustained Benefit 20 Years After Reperfusion July 5, 2005:15–20atients (two patients allocated to reperfusion therapy and
wo allocated to conventional treatment) who had moved
broad could not be retrieved, and the last available
ollow-up data were used.
tatistical analysis. Continuous variables were compared
y Student t test and categorical variables by chi-square
ests. Cumulative survival analyses were constructed using
he Kaplan-Meier method. Among patient subgroups, the
antel and Haenszel log-rank test was used to compare
urvival and event-free survival curves.
The expected survival in a reference population was
alculated using age- and gender-specific mortality data
rom the Netherlands in 1983, and compared with survival
n patients after MI. Because the mean age of our infarct
tudy population was 56 years and 80% were male, mortality
isks were weighted accordingly.
The Cox proportional hazards model was used to identify
ndependent risk factors for 20-year mortality. Preselected
atient baseline characteristics were: age, gender, previous
I, infarct site, Killip class at admission, time from onset to
reatment allocation, and sum of ST-segment elevation at
dmission. In the analyses, the following data were also
ollected in-hospital: atrial fibrillation and ventricular fibril-
ation/flutter, infarct size as assessed from cardiac enzyme
elease, the (in)ability to perform an exercise test before
ischarge, extent and severity of coronary artery disease, and
eft ventricular function. Myocardial reinfarction may
hange a patient’s prognosis, therefore, a time-dependent
ox proportional hazards model was used to investigate the
ffect of myocardial reinfarction during follow-up on sub-
equent mortality using BMDP statistical software (Univer-
ity of California, Berkeley, California).
ife expectancy. Life expectancy after MI, with or without
eperfusion therapy, was calculated from the area under the
aplan-Meier curves truncated at 20 years (11). To calcu-
ate the exact life expectancy, the curves were extended
eyond 20 years using the age- and gender-specific mortal-
ty data from the reference population in the Netherlands,
ssuming that those post-MI patients who had survived 20
ears would have similar further life expectancy as their age-
nd gender-matched peers. The yearly mortality rate of a
6-year-old male in the Netherlands is around 4%.
ESULTS
atients were randomized to receive either reperfusion
herapy (n  269) or conventional treatment (n  264).
Abbreviations and Acronyms
CI  confidence interval
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous coronary interventionhe mean age at enrollment was 56 years (range 28 to 71
H
iears), 82% were men, 22% had previous infarction, and
6% were admitted with an anterior infarction (Table 1).
ortality. The 30-day mortality was 6.5% after reperfu-
ion therapy and 11.8% after conventional treatment
Table 1). During a median follow-up of 21 years (range 19
o 23 years), 361 patients (69%) died, 168 patients allocated
o reperfusion therapy (64%) and 193 controls (74%). The
umulative 10-, 15-, and 20-year survival rates were 69%,
8%, and 37% in patients treated with reperfusion therapy
nd 59%, 38%, and 27% in the conventional group, respec-
ively (Fig. 1). After one year, the two curves were approx-
mately parallel. Thus, the 10% early (one-year) survival
enefit by reperfusion therapy was sustained throughout 20
ears (log-rank test, p  0.005). The corresponding ex-
ected survival of the age- and gender-specific reference
opulation after 10, 15, and 20 years was 86%, 73%, and
6% (Fig. 1). In the patients with successful reperfusion
herapy (80%), the cumulative 10-, 15-, and 20-year survival
ates were 78%, 55%, and 45%, respectively. This was
ignificantly higher than in the total reperfusion group (p 
.05).
umulative 20-year survival. Overall, there was an abso-
ute benefit of 105 lives saved per 1,000 treated patients
95% confidence interval [CI] 25 to 185). This benefit was
pparent in all subgroups (Table 2). Larger benefit was
bserved in younger patients when compared with elderly
able 1. Characteristics and Hospital Outcome According to
eperfusion or Conventional Treatment
Reperfusion
Therapy
(n  269)
Conventional
Treatment
(n  264)
p Valuen (%) n (%)
linical characteristics,
presentation
Age (mean [SD]) (yrs) 56 (9) 56 (8) 0.9
Male 217 (81%) 222 (84%) 0.3
Previous MI 56 (21%) 60 (23%) 0.6
History of angina 214 (80%) 216 (82%) 0.5
ST-segment elevation
1.2 mV
129 (53%) 147 (61%) 0.1
Killip class III/IV 12 (5%) 11 (4%) 0.9
Anterior MI 129 (48%) 116 (44%) 0.4
Time to treatment 2 h 192 (71%) 200 (76%) 0.3
linical outcome
VT/VF 120 (45%) 105 (40%) 0.3
Infarct size (HBDH)
1,100
69 (30%) 101 (46%) 0.005
LV ejection fraction
40% (%)
51 (20%) 67 (28%) 0.04
Inability exercise test 69 (26%) 68 (26%) 1.0
30-day mortality 17 (6.5%) 31 (11.8%) 0.0001
ngiography
Extent of coronary disease 0.3
One-vessel 95 (47%) 75 (40%)
Two-vessel 73 (36%) 76 (40%)
Three-vessel 33 (16%) 37 (20%)BDH  hydroxybutyrate dehydrogenase; LV  left ventricular; MI  myocardial
nfarction; VT/VF  ventricular tachycardia/fibrillation.
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July 5, 2005:15–20 Sustained Benefit 20 Years After Reperfusion60 years), in patients with anterior MI, and in patients
reated within 2 h after the onset of symptoms.
ife expectancy. Life expectancy was 12.4 years after
onventional therapy and was increased by reperfusion
herapy to 15.2 years, a difference of 2.8 years (Table 2). The
eneficial effect of reperfusion therapy as compared with
onventional treatment was apparent in all subgroups stud-
ed. In patients with extensive ST-segment elevation, there
as a beneficial effect of 3.9 years by reperfusion therapy.
atients with an anterior infarct had a gain of 3.4 life-years
ompared with 2.5 years after inferior infarction. In patients
igure 1. Cumulative survival after reperfusion therapy or conventional
herapy.
able 2. Twenty-Year Cumulative Mortality, Absolute Benefits o
pecific Subgroups
20-Year Cumulative Survival (%)*
Reperfusion Conventional p†
verall 37.2 26.7 0.01
ge
60 yrs 18.4 15.7 0.16
60 yrs 50.6 33.0 0.0008
ex
Male 37.2 26.9 0.01
Female 37.3 26.2 0.20
rior MI
Yes 25.0 16.7 0.23
No 40.5 29.7 0.016
ite of MI
Anterior 33.3 20.9 0.014
Inferior 40.9 31.4 0.08
T-segment elevation
1.2 mV 29.9 19.6 0.04
1.2 mV 46.9 31.2 0.03
ime to treatment
2 h 34.7 28.6 0.16
2 h 38.2 26.1 0.01
nfarct size
HBDH 1,100 27.8 15.0 0.03
HBDH 1,100 45.9 34.4 0.05
V ejection fraction
40% 18.1 6.6 0.01
40% 46.7 37.2 0.08
xtent of coronary disease
Multivessel 32.1 22.9 0.03
Single vessel 46.2 36.4 0.2120-year cumulative survival rates (%) are derived from Kaplan-Meier lifetables; †p  log-
CI  confidence interval; HBDH  hydroxybutyrate dehydrogenase; LV  left ventriith early treatment (2 h onset complaints), the gain in
ife expectancy was 3.6 years. The greatest benefit was
chieved in the subgroup of patients with extensive (ST-
egment elevation 1.2 mV) anterior infarction, treated
ithin 2 h of symptom onset. In these patients life expect-
ncy was only 9.0 years with conventional therapy, increas-
ng by 4.9 years to 13.9 years with reperfusion therapy.
We compared these results with our earlier reported life
xpectancy model based on one-year outcome (Table 3) (8).
verall, the earlier model underestimated the beneficial
ffect of reperfusion therapy by a factor of two. Instead of an
stimated gain of 1.5 life-years, we observed a 2.8-life-years
enefit after reperfusion therapy. In the reference popula-
ion, in the 1980s, the expected survival was 21.1 years. In
hose patients suffering from MI, 8.7 years of these 21.1
ife-years were lost when treated conventionally. About
ne-third of this loss (2.8 years) could be restored by timely
eperfusion therapy.
e-infarction and revascularization. An excess of re-
nfarction was observed during the first four years after
eperfusion therapy (Fig. 2A). The rate of re-infarction was
articularly high in the first year: 14.5% and 5.9% in the
eperfused and control patients, respectively. In years 2 to 4,
he annual re-infarction rate averaged about 3.0% after
perfusion Therapy, and Life Expectancy Overall and in
solute Benefit
eperfusion per
000 (95% CI)
Life Expectancy (yrs)
Reperfusion Conventional Benefit (95% CI)
05 (25, 185) 15.2 12.4 2.8 (0.5, 5.1)
27 (53, 153) 11.0 9.1 1.9 (1.4, 5.2)
76 (74, 284) 18.4 14.1 4.3 (1.6, 7.0)
03 (15, 191) 15.1 12.5 2.6 (0.3, 4.9)
11 (78, 300) 15.3 12.0 3.3 (1.4, 7.6)
83 (65, 231) 10.7 9.4 1.3 (3.5, 6.1)
08 (16, 200) 16.4 13.3 3.1 (0.7, 5.6)
24 (13, 235) 14.1 10.7 3.4 (0.3, 6.6)
95 (17, 207) 16.2 13.7 2.5 (0.4, 5.1)
03 (8, 198) 13.3 11.3 2.0 (0.1, 5.1)
57 (26, 288) 17.7 13.8 3.9 (0.6, 7.3)
61 (94, 216) 14.6 12.5 2.1 (1.1, 5.4)
21 (28, 214) 15.7 12.1 3.6 (0.6, 5.3)
28 (20, 236) 11.6 8.5 3.1 (0.4, 6.3)
15 (1, 229) 17.9 15.1 2.8 (0.0, 6.0)
05 (20, 218) 10.7 6.6 4.1 (0.4, 5.4)
95 (25, 215) 17.7 15.1 2.6 (0.5, 5.2)
92 (5, 179) 13.8 11.1 2.7 (0.1, 5.0)
98 (51, 247) 17.5 14.8 2.7 (1.2, 6.6)f Re
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cular; MI  myocardial infarction.
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Sustained Benefit 20 Years After Reperfusion July 5, 2005:15–20eperfusion therapy and 1.5% in controls, dropping to 1.2%
n years 6 to 10, and below 0.5% from year 11 onward in
oth treatment groups. After conventional treatment, the
ame coronary artery was involved in 44% of the re-
nfarctions and in 64% after reperfusion therapy.
Coronary revascularization in addition to immediate
eperfusion therapy during hospitalization was not com-
on. Only 7 patients underwent revascularization (all per-
utaneous coronary intervention [PCI]) in the reperfusion
roup and 10 patients in the conventional group. After
ischarge, coronary revascularization procedures were per-
ormed predominantly in the first year after the index
nfarct, somewhat more frequently in the reperfusion group
reperfusion: 20.4%, conventional: 17.0%) (Fig. 2B). After
he first year, revascularization was infrequent and not
ignificantly different among the treatment groups (reper-
usion: 1.0%/year; conventional: 0.7%/year). Of 46 patients
n whom elective coronary angioplasty was performed as
art of the initial reperfusion process, 39% underwent repeat
igure 2. (a) Yearly incidence of myocardial re-infarction. (b) Yearly
Table 3. Life Expectancy (Years) Comparing a
1-Yea
Reperfusion
All patients 16.8
Inferior infarction 17.0
Anterior infarction 16.5
Anterior infarction
Rx 2 h and STE 1.2 mV 16.3
Rx 2 h and STE 1.2 mV 16.6
Rx  treatment; STE  ST-segment elevation.o
ncidence of revascularization (coronary bypass surgery or coronary angio-
lasty). *Five-year average.evascularization (7 PCI and 13 coronary artery bypass
rafting). This was similar to those reperfused patients
ithout acute PCI. Event-free survival, without recurrent
nfarction or revascularization was similar in both treatment
roups: 46% at 5 years, 32% at 10 years, and 14% after 20
ears.
nivariable andmultivariable predictors ofmortality. Predic-
ors of 20-year mortality were age, a previous MI,
nterior infarction, extensive ST-segment elevation, and
evere heart failure or cardiogenic shock (Table 4).
owever, after inclusion of parameters representing
eperfusion therapy and subsequent clinical course, these
aseline characteristics were replaced by more precise
easurements of infarct size, left ventricular function,
nd extent of coronary disease. Yet, adjusting for all other
aseline characteristics, reperfusion therapy remained an
mportant independent predictor of lower mortality (haz-
rd ratio [HR] 0.7; 95% CI 0.6 to 0.8) as compared with
onventional therapy (Table 4). Also, nonfatal myocar-
ial re-infarction was a predictor of mortality using the
djusted time-dependent Cox model (HR 1.7; 95% CI
.3 to 2.2).
ISCUSSION
his follow-up study demonstrates that the early survival
enefits of reperfusion therapy are sustained for 20 years,
nd probably life-long. The survival benefit of reperfusion
herapy was 6% at hospital discharge, 10% at one year, and
emained about 10% throughout 20 years of follow-up.
fter 20 years, survival with conventional therapy was only
7%, which is approximately one-half of the survival in the
ormal reference population (56%). With reperfusion ther-
py (survival 37%) about one-third of this loss could be
estored. These observations extend earlier reports on pa-
ients followed for a decade after reperfusion therapy or
onventional therapy (4–7). Reperfusion therapy with in-
racoronary streptokinase (followed in some patients by
escue PCI), was a predictor of long-term survival, inde-
endent of baseline characteristics, infarct size, or cardiac
unction at hospital discharge. This suggests that the ben-
fits of reperfusion therapy are not only related to limitation
f infarct size and preservation of left ventricular function,
ut also to the infarct zone. Re-infarction, which often
ear Model (8) With a 20-Year Model
del 20-Year Model
onventional Reperfusion Conventional
15.3 15.2 12.4
16.3 16.2 13.7
14.1 14.1 10.7
12.7 13.9 9.0
15.1 14.7 14.81-Y
r Mo
Cccurred in the same territory as the index infarct, was an
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July 5, 2005:15–20 Sustained Benefit 20 Years After Reperfusionmportant predictor of subsequent mortality using a time-
ependent Cox model.
In the two decades since this early study, reperfusion
herapy has evolved. It is likely that the benefits of current
herapy with primary PCI and stenting will be larger than
he important benefit reported by us. Indeed, successful
eperfusion can now be achieved in more than the 80% of
ur study, while the incidence of re-infarction has also been
ignificantly reduced.
The survival benefit after reperfusion therapy at one
onth was 6%, increasing to 10% at one year and beyond.
o additional benefit of reperfusion therapy was observed
fter the first year, in spite of the better left ventricular
unction at hospital discharge. This may be due to the excess
f re-infarction, with associated loss of ventricular function,
s was observed during the first years in the reperfusion
roup.
We had the unique opportunity to verify the life expect-
ncy model, which was developed on the basis of earlier
nfarct studies and one-year outcome (8). In that report, the
xtrapolated life expectancy was 15.3 years with conven-
ional therapy and 16.8 years after early reperfusion, a gain
f 18 months. After extended follow-up in the current
tudy, we were able to calculate life expectancy more
ccurately and we found that life expectancy was overesti-
ated by one to three years with the original one-year
odel (Table 4), but we also observed an almost two-fold
reater (2.8 years) gain in life expectancy in favor of
eperfusion therapy. Apparently the (necessary) assumptions
n the original model with limited follow-up were not
ccurate. These observations indicate that estimates of life
Table 4. Univariable and Multivariable Predict
at Hospital Discharge: Demographics, Presenta
Univa
HR
Baseline characteristics, presentation
Age (yrs) 1.04 1
Male 1.0
Previous MI 1.7
History of angina 1.2
ST-segment elevation 1.2 mV 1.5
Killip class III/IV 2.0
Anterior MI 1.3
Reperfusion therapy
Reperfusion therapy 0.7
Infarct size (HBDH) 1,100 1.8
Time to treatment 2 h 1.0
Clinical course in hospital
VT/VF 1.1
LV ejection fraction 40% 2.6
Multivessel disease 1.8
Inability to perform an exercise test 2.1
Post-discharge
Nonfatal reinfarction 1.5
*Only baseline characteristics; †all variables.
CI  confidence interval; HR  hazard ratio; LV  le
tachycardia/fibrillation.xpectancy and cost-effectiveness analyses of medical inter- Hentions should be interpreted with caution as long as true
ong-term follow-up data are lacking. Therefore, true long-
erm follow-up studies of randomized trials should be
onducted more frequently.
tudy limitations. The treatment of patients with acute
I has evolved in major ways since this trial was conducted
etween 1981 and 1985. Intracoronary streptokinase, al-
hough apparently effective, is no longer given and has been
eplaced by intravenous administration of different fibrino-
ytic agents (streptokinase, alteplase, reteplase, tenecteplase)
r, preferably, direct PCI (12,13). Nevertheless, our main
nding, that reestablishment of coronary patency improves
ong-term survival, will remain valid. In fact, it is now to be
xpected that direct PCI has further improved life expect-
ncy after reperfusion therapy, because direct PCI is asso-
iated with better reperfusion as well as lower re-infarction
ates and fewer strokes than thrombolytic therapy (12).
ecause of limited availability of angioplasty centers world-
ide, only a minority of patients with evolving MI undergo
rimary angioplasty (14). Therefore, at least in the near
uture, fibrinolytic therapy will remain an important method
or reperfusion. The patients in our study were treated with
spirin or coumadin and with beta-blockers. In addition, it
as been shown that systematic treatment with statins and
ngiotensin-converting enzyme inhibitors further reduces
he incidence of mortality and re-infarction (13). Taken
ogether, newer, more effective methods for reperfusion
herapy and more effective secondary prevention may be
xpected to further extend the gain in life expectancy as
bserved in our study. The subgroup analyses in the present
tudy may be questioned because of the lack of power.
f Long-Term Mortality That Were Available
, and In-Hospital Clinical Events
Multivariate* Multivariate†
CI HR 95% CI HR 95% CI
.06 1.05 1.03–1.06 1.03 1.01–1.05
.2
.2 1.7 1.3–2.1
.5
.9 1.6 1.3–1.9
.2 1.9 1.2–3.0
.6 1.4 1.2–1.7
.9 0.7 0.6–0.8 0.7 0.6–0.8
.2 1.3 1.1–1.8
.2
.4
.2 2.7 1.3–2.2
.3 1.4 1.1–1.8
.6 1.6 1.1–2.2
.9 1.7 1.3–2.2
ricular; MI  myocardial infarction; VT/VF  ventricularors o
tion
riate
95%
.03–1
0.8–1
1.4–2
1.0–1
1.2–1
1.2–3
1.1–1
0.6–0
1.4–2
0.8–1
0.9–1
2.0–3
1.4–2
1.7–2
1.2–1owever, our data confirms the findings of other studies
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Sustained Benefit 20 Years After Reperfusion July 5, 2005:15–2015), that reperfusion therapy is beneficial in all patients
ith evolving MI, and particularly beneficial when admin-
stered early after symptom onset in patients with extensive
anterior) infarcts.
onclusions. This long-term follow-up study demon-
trates that very early aggressive reperfusion therapy im-
roves survival after MI at least beyond the second decade.
eperfusion therapy prolongs life almost three years and
estores one-third of the loss in life-years by the infarct.
hese findings reemphasize that all efforts should be made
o identify patients with evolving MI, and to provide rapid,
ffective reperfusion therapy without delay.
eprint requests and correspondence: Dr. Ron T. van Domburg,
rasmus Medical Center, Thoraxcentrum, Ba 559, Dr Molewater-
lein 40, 3015 GD Rotterdam, the Netherlands. E-mail:
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